Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

Koen Van Besien, Rangesh Kunavakkam, Gaby Rondon, Marcos De Lima, Andrew Artz, Betul Oran, Sergio Giralt

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes'. Together they form a unique fingerprint.

Medicine & Life Sciences